Overview

This trial is active, not recruiting.

Condition alzheimer's disease
Treatment dimebon
Phase phase 1
Sponsor Medivation, Inc.
Start date May 2008
End date November 2008
Trial size 21 participants
Trial identifier NCT00704782, DIM13

Summary

The purpose of this study is to assess the safety and efficacy of Dimebon in combination with donepezil (Aricept) in the treatment of Alzheimer's disease.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Measure
To assess the safety of Dimebon in combination with donepezil (Aricept)
time frame: week 12

Eligibility Criteria

Male or female participants at least 50 years old.

Inclusion Criteria: - Alzheimer's disease - On donepezil (Aricept) - Caregiver who cares for the patient at least 5 days per week Exclusion Criteria: - Unstable medical illnesses or significant hepatic or renal disease - Other primary psychiatric or neurological disorders

Additional Information

Official title An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
Trial information was received from ClinicalTrials.gov and was last updated in June 2009.
Information provided to ClinicalTrials.gov by Medivation, Inc..